This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NamePirarubicin
Accession NumberDB11616
TypeSmall Molecule
GroupsInvestigational
DescriptionNot Available
Structure
Thumb
Synonyms
Adriamycin, tetrahydropyranyl
Theprubicin
THP-Adm
THP-Doxorubicin
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Pirarubicin hydrochlorideE7V83174BE 95343-20-7ZPHYPKKFSHAVOE-YZIXBPQXSA-NDetails
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIID58G680W0G
CAS number72496-41-4
WeightAverage: 627.643
Monoisotopic: 627.231575635
Chemical FormulaC32H37NO12
InChI KeyKMSKQZKKOZQFFG-YXRRJAAWSA-N
InChI
InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21+,22-,31+,32-/m0/s1
IUPAC Name
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yloxy]oxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
SMILES
[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(C=CC=C2OC)C4=O)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O[C@]1([H])CCCCO1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pirarubicin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Alendronic acidPirarubicin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Pirarubicin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Pirarubicin.Approved, Investigational
AmpicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideHMPL-004 may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
ApocyninAcetovanillone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
Atracurium besylatePirarubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Pirarubicin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Pirarubicin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Pirarubicin.Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Pirarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Pirarubicin.Approved, Investigational
Botulinum Toxin Type APirarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BPirarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pirarubicin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirarubicin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Pirarubicin.Approved
CarbenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Carbenicillin.Approved
CarboplatinPirarubicin may increase the ototoxic activities of Carboplatin.Approved
CarprofenCarprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateTrisalicylate-choline may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Cisatracurium besylatePirarubicin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Pirarubicin.Approved
Clodronic AcidPirarubicin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethatePirarubicin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pirarubicin.Approved, Investigational
CyclosporinePirarubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DecamethoniumPirarubicin may increase the respiratory depressant activities of Decamethonium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pirarubicin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pirarubicin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pirarubicin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Pirarubicin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirarubicin.Approved, Investigational
Domoic AcidPirarubicin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chloridePirarubicin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
E-6201E6201 may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
EpirizoleEpirizole may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pirarubicin.Approved
EtanerceptEtanercept may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
Etidronic acidPirarubicin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
FenbufenFenbufen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
FingolimodPirarubicin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FloctafenineFloctafenine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Flucloxacillin.Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Pirarubicin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Pirarubicin.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Pirarubicin is combined with G17DT.Investigational
Gallamine TriethiodidePirarubicin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HigenamineHigenamine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
IbandronatePirarubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Pirarubicin is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pirarubicin is combined with INGN 225.Investigational
IsoxicamIsoxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Leflunomide.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
LornoxicamLornoxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Pirarubicin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
MecamylaminePirarubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Pirarubicin can be decreased when it is combined with Meticillin.Approved
MetocurinePirarubicin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodidePirarubicin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Pirarubicin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumPirarubicin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Pirarubicin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Natalizumab.Approved, Investigational
NeosaxitoxinPirarubicin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Pirarubicin.Experimental
OlopatadineOlopatadine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
OuabainOuabain may decrease the cardiotoxic activities of Pirarubicin.Approved
OxacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirarubicin.Approved, Vet Approved
PamidronatePirarubicin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumPirarubicin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirarubicin.Approved, Investigational
PipecuroniumPirarubicin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Pirarubicin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Pirarubicin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Pirarubicin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
RapacuroniumPirarubicin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Experimental, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Pirarubicin is combined with CDX-110.Investigational
RisedronatePirarubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumPirarubicin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Pirarubicin.Approved
SalicylamideSalicylamide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
SeratrodastSeratrodast may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pirarubicin.Approved
SRP 299The risk or severity of adverse effects can be increased when Pirarubicin is combined with SRP 299.Investigational
SRT501SRT501 may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
SuccinylcholinePirarubicin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Pirarubicin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Pirarubicin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pirarubicin.Approved, Investigational
TazobactamThe serum concentration of Pirarubicin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m medronatePirarubicin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
Tenofovir disoproxilThe serum concentration of Pirarubicin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Pirarubicin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
Tiludronic acidPirarubicin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
TofacitinibPirarubicin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Pirarubicin.Approved
TranilastTranilast may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pirarubicin.Approved, Investigational
TubocurarinePirarubicin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Pirarubicin.Approved
VecuroniumPirarubicin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidPirarubicin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesL01DB08 — Pirarubicin
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingPreventionBladder Recurrence / Nephroureterectomy / Upper Tract Urothelial Carcinoma1
2RecruitingPreventionBladder Recurrence / Upper Tract Urothelial Carcinoma1
2RecruitingTreatmentAntineoplastic Combined Chemotherapy Protocols1
2RecruitingTreatmentIntravesical Instillation1
2Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
2, 3Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentNeoplasms, Breast1
3RecruitingTreatmentHepatocellular,Carcinoma1
4RecruitingTreatmentCancer, Breast1
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.301 mg/mLALOGPS
logP2.06ALOGPS
logP2.05ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)7.99ChemAxon
pKa (Strongest Basic)9.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area204.3 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity157.38 m3·mol-1ChemAxon
Polarizability64.85 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassAnthracyclines
Sub ClassNot Available
Direct ParentAnthracyclines
Alternative ParentsTetracenequinones / Aminoglycosides / Anthraquinones / O-glycosyl compounds / Tetralins / Anisoles / Aryl ketones / Alkyl aryl ethers / Phenols / Oxanes
SubstituentsAnthracycline / Anthracyclinone-skeleton / Aminoglycoside core / Tetracenequinone / 9,10-anthraquinone / 1,4-anthraquinone / Anthracene / Glycosyl compound / O-glycosyl compound / Tetralin
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Drug created on August 25, 2016 16:58 / Updated on August 02, 2017 17:38